Haemonetics Corporation $HAE Shares Acquired by May Hill Capital LLC

May Hill Capital LLC grew its position in Haemonetics Corporation (NYSE:HAE) by 100.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 44,696 shares of the medical instruments supplier’s stock after acquiring an additional 22,348 shares during the quarter. May Hill Capital LLC’s holdings in Haemonetics were worth $3,582,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. John G Ullman & Associates Inc. raised its stake in shares of Haemonetics by 13.8% during the fourth quarter. John G Ullman & Associates Inc. now owns 13,600 shares of the medical instruments supplier’s stock worth $1,090,000 after purchasing an additional 1,650 shares during the last quarter. Isthmus Partners LLC raised its stake in shares of Haemonetics by 9.6% during the fourth quarter. Isthmus Partners LLC now owns 67,610 shares of the medical instruments supplier’s stock worth $5,419,000 after purchasing an additional 5,908 shares during the last quarter. Allworth Financial LP raised its stake in shares of Haemonetics by 390.8% during the fourth quarter. Allworth Financial LP now owns 746 shares of the medical instruments supplier’s stock worth $60,000 after purchasing an additional 594 shares during the last quarter. World Investment Advisors purchased a new stake in shares of Haemonetics during the fourth quarter worth approximately $246,000. Finally, Crossmark Global Holdings Inc. purchased a new stake in shares of Haemonetics during the fourth quarter worth approximately $218,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

HAE has been the subject of several analyst reports. Barrington Research cut their price target on Haemonetics from $94.00 to $89.00 and set an “outperform” rating for the company in a research note on Tuesday, May 12th. Robert W. Baird set a $67.00 price target on Haemonetics in a research note on Friday, May 8th. JPMorgan Chase & Co. cut their price target on Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. BTIG Research restated a “buy” rating and set a $88.00 price target on shares of Haemonetics in a research note on Friday, February 6th. Finally, Mizuho cut their price target on Haemonetics from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Monday, April 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $79.33.

Haemonetics Trading Down 1.4%

NYSE:HAE opened at $56.34 on Friday. The stock has a fifty day moving average price of $58.54 and a two-hundred day moving average price of $66.75. The stock has a market capitalization of $2.62 billion, a price-to-earnings ratio of 27.89, a PEG ratio of 1.13 and a beta of 0.53. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.87 and a current ratio of 2.95. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $87.32.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.01. The firm had revenue of $346.35 million during the quarter, compared to analysts’ expectations of $336.83 million. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.Haemonetics’s revenue was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.24 earnings per share. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, sell-side analysts anticipate that Haemonetics Corporation will post 5.23 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.